Monte Rosa Therapeutics, Inc. financial statements
Income statement, balance sheet and cash flow statement for the last 6 fiscal years, taken from the XBRL data Monte Rosa Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0
75.6
124
Research and development
24
57.2
85.1
111
122
142
General and administrative
4.01
15.7
27.3
32
35.2
36.4
Operating expenses
28
72.9
112
143
157
178
Operating income
-28
-72.9
-112
-143
-81.1
-54.2
Other non-operating income
-7.87
-1.08
3.88
8.3
11
14.5
Pre-tax income
-10.1
-9.88
-109
-135
-70.1
-39.7
Income tax
0
0.34
2.57
-1.1
Net income
-35.9
-74
-109
-135
-72.7
-38.6
EBITDA
-27.5
-70.8
-109
-137
-73
-45.9
EPS, basic
-23.65
-2.96
EPS, diluted
-23.65
-2.96
Shares, basic (weighted)
1.52
25
47.2
51.4
73.9
83.1
Shares, diluted (weighted)
1.52
25
47.2
51.4
73.9
83.1
Balance sheet
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
41.7
346
54.9
128
224
130
Other current assets
1.89
2.6
4.44
3.29
5.12
4.48
Total current assets
43.6
349
276
236
377
393
Property, plant and equipment
4.62
12.3
27.1
33.8
29.5
26
Lease right-of-use assets
0
34.8
28.8
26.8
24.4
Other non-current assets
0
0.28
0.35
0.12
0.15
Total assets
49.4
366
342
304
439
449
Accounts payable
7.07
6.56
7.86
11.2
17.2
3.55
Accrued liabilities
1.13
4.3
5.62
7.59
18.8
26.7
Deferred revenue
0
17.7
117
29.6
Total current liabilities
29.3
16.6
25.6
46.6
157
64.2
Lease liabilities
0
43.9
42.9
39
34.8
Total liabilities
30.3
18.8
71
125
216
216
Paid-in capital
0.4
472
504
548
665
714
Retained earnings
-48.1
-122
-231
-366
-439
-477
Other comprehensive income
-1.06
-2.02
-1.75
-2.72
-3.36
-3.83
Shareholders' equity
-48.7
348
271
179
223
233
Total equity
-48.7
348
271
179
223
233
Total liabilities and equity
49.4
366
342
304
439
449
Shares outstanding
1.69
46.5
49.3
50.1
61.5
65.5
Cash flow statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-35.9
-74
-109
-135
-72.7
-38.6
Depreciation and amortization
0.54
2.13
3.75
6.22
8.12
8.36
Stock-based compensation
0.35
5.2
11.7
16.7
18.1
18.9
Change in payables
3.44
-0.71
-0.74
5.76
6.25
-13.7
Cash from operations
-23.1
-59.4
-92.5
-43.8
42
-22.8
Capital expenditures
-3.39
-9.73
-12.9
-19
-3.99
-4.7
Purchases of investments
0
-384
-103
-230
-377
Sales and maturities of investments
0
0
45.6
0
Cash from investing
-3.39
-9.65
-219
88.8
-44.5
-102
Stock issued
0
0
20.1
0
1.06
5.72
Dividends paid
0
0
0
0
0
Cash from financing
60.1
378
20.5
27.5
98.9
30.4
Net change in cash
33.6
309
-291
72.5
96.4
-94.3
Free cash flow
-26.4
-69.1
-105
-62.8
38
-27.5
Income taxes paid
2.64
5.18
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $11.77 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-633.0%
Operating income / revenue.
EBITDA margin
-604.8%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-570.8%
Pre-tax income / revenue.
Net margin
-560.9%
Net income / revenue.
FCF margin
-111.7%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-83.8%
Cash from operations / revenue.
Return on equity (ROE)
-33.1%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-23.3%
Net income / average total assets.
Return on invested capital (ROIC)
-36.2%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
594.2%
Research and development expense / revenue.
Stock-based pay / revenue
71.7%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
27.9%
Capital expenditures / revenue.
D&A / revenue
28.3%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
63.5%
Revenue vs the same period a year earlier. Only from a positive base.
Operating cash flow growth, 1y
-154.3%
Operating cash flow vs the same period a year earlier. Only from a positive base.
Free cash flow growth, 1y
-172.3%
Free cash flow vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
4.5%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-5.0%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
2.3%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
9.4%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
55.5%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
12.4%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
20.7%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
122.7%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
10.6x
Current assets / current liabilities.
Quick ratio
1.51x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
1.51x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.28
Revenue / diluted weighted shares.
FCF per share
-$0.32
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.24
Cash from operations / diluted weighted shares.
Book value per share
$5.72
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
35.0x
Market cap / revenue.
P/B
2.06x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
2.06x
Market cap / tangible book value, when positive.
EV/Sales
31.8x
Enterprise value / revenue.
FCF yield
-3.2%
Free cash flow / market cap.
Earnings yield
-16.0%
Net income / market cap (the inverse of P/E).
Dividend yield
0.0%
Dividends paid over the period / market cap.
Shareholder yield
0.0%
(Dividends paid + share buybacks) / market cap.
What was Monte Rosa Therapeutics, Inc.'s revenue in fiscal 2025?
Monte Rosa Therapeutics, Inc. reported revenue of $123.7M for fiscal 2025, 63.5% higher than the year before.
Was Monte Rosa Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $38.6M.
How much free cash flow did Monte Rosa Therapeutics, Inc. generate in fiscal 2025?
Cash from operations of $22.8M minus capital expenditures of $4.7M left free cash flow of -$27.5M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.